PROGNOSIS OF OPHTHALMOPATHOLOGY IN CHRONIC MYELOPROLIFERATIVE DISEASES

Chronic myeloproliferative diseases (CMPD) are a group of hemoblastoses that occur with impaired myelopoiesis. Quite often there are mentions of damage to eye tissues in CMPD. But despite this, there is not enough information in the literature about the factors leading to the development of ophthalmological disorders in this pathology.

The objective of the work is to determine the predictors of ophthalmopathology in CMPD.

Material and methods. The study included 78 patients with CMPD (main group) and 61 volunteers without hemoblastoses (control group). The groups were comparable in gender and age. All the examined patients underwent comprehensive ophthalmological and laboratory diagnostics.

Results. Eye pathology in patients with CMPD was significantly more common than in those without hemoblastoses (for the anterior segment it was p<0,05; for the posterior segment it was p><0,01). Platelet levels in CMPD were higher compared to the control group (p><0,05). Eye disorders in patients developed against the background of a significant increase in the age and duration of the disease (p><0,05). Conclusions. Mature age, prolonged course of CMPD, and altered laboratory blood counts may be possible predictors of the development of eye disorders in such patients.><0,05; for the posterior segment it was p<0,01) . Platelet levels in CMPD were higher compared to the control group (p<0,05) . Eye disorders in patients developed against the background of a significant increase in the age and duration of the disease (p<0,05).

Conclusions. Mature age, prolonged course of CMPD, and altered laboratory blood counts may be possible predictors of the development of eye disorders in such patients.

1. Rudneva L.F. [et al.] Gemoblastozy. Osobennosti porazheniya glaz (Hemoblastosis. Features of eye damage). Tyumen': Konovalov I. S. 2020:90. (In Russ).

2. Yusef N. Yu. [et al.] Clinical manifestations and mechanisms of development of eye damage in hemoblastosis. Ophthalmology.2023;20(3): 528–535. (In Engl). DOI 10.18008/1816–5095-2023-3-528-535.

3. Sposob prognozirovanija nalichija patologii horiokapilljarov v proekcii makuljarnoj oblasti pri hronicheskih mieloproliferativnyh zabolevanijah (A method for predicting the presence of choriocapillary pathology in the projection of the macular area in chronic myeloproliferative diseases): patent № 2798930 C1 Ros. Federacija; zajavl. 30.12.2022: opubl. 29.06.2023; Bjul. 19:8. (in Russ).

4. Sposob prognozirovanija nalichija oftal'mologicheskih narushenij pri hronicheskom mieloidnom lejkoze (Method of predicting the presence of ophthalmic disorders in chronic myeloid leukemia): patent № 2803230 C1 Ros. Federacija; zajavl. 17.01.2023: opubl. 11.09.2023; Bjul. № 26:7 (in Russ).

5. Sposob prognozirovanija nalichija patologii vitreomakuljarnogo interfejsa pri hronicheskom mieloidnom lejkoze (Method of predicting the presence of pathology of the vitreomacular interface in chronic myeloid leukemia): patent № 2803690 C1 Ros. Federacija; zajavl. 17.01.2023: opubl. 19.09.2023; Bjul. № 26:8 (in Russ).

6. Efremova E. V. [et al.] Problems of thrombotic events in PH-negative myeloproliferative neoplasms. Hematology. Transfusiology. Eastern Europe. 2022; 8(1):19-28. (in Russ).

7. Moshetova L. K. [et al.] Contemporary interpretations of ophthalmological manifestations of chronic myeloproliferative neoplasms. Bulletin of the Russian Academy of Medical Sciences.2023;78(3):208–212. (in Russ). DOI 10.15690/vramn2277.

8. Seraly M. P. [et al.] A unique case of chronic myeloid leukemia presenting as monocular vision loss with unilateral retinopathy. Am. J. Ophthalmol. Case Rep. 2019;(14):67–69. (In Engl). DOI 10.1016/j.ajoc.2019.02.003.

9. Qiu H. B. [et al.] Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2018;18(3):460–466. (In Engl). DOI 10.1038/tpj.2017.40.

10. Liisborg C., Hasselbalch H. C., Sorensen T. L. Ocular manifestations in patients with Philadelphia-negative myeloproliferative neoplasms. Cancers (Basel). 2020;12(3):573. (In Engl). DOI 10.3390/cancers12030573.

11. Mohamed S. F. [et al.] Ophthalmologic manifestations as initial presentation of patients with chronic myeloid leukemia: report of two cases. Case Rep. Oncol. 2020;13(1):7–11. (In Engl). DOI 10.1159/000504928.

12. Yassin M. A. [et al.] Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: A review. Surv. Ophthalmol. 2022;67(2):530–543 (In Engl). DOI 10.1016/j.survophthal.2021.07.001.

13. Pretel-Irazabala M., Tuneu-Vallsb A., Ormaechea-Pérezb N. Adverse skin effects of imatinib, a tyrosine kinase inhibitor. Actas DermoSifiliográficas. 2014;(105):655-662. (In Engl). DOI 10.1016/j.adengl.2014.07.010.

14. Rane P. R. [et al.] Chronic myeloid leukaemia presenting as bilateral retinal haemorrhages with multiple retinal infiltrates. J. Clin. Diagn. Res. 2016;10(5):4–5. (In English). DOI 10.7860/JCDR/2016/18215.7822.

15. Rosenthal A. R. Ocular manifestations of leukemia. Ophthalmology. 1983;90(8):899-905. (In Engl). DOI 10.1016/s0161-6420(83)80013-x.